Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Judith Hugh"'
Autor:
Atul Batra, Nancy A. Nixon, Gloria Roldan-Urgoiti, Malek B Hannouf, Tasnima Abedin, Judith Hugh, Karen King, Gilbert Bigras, Tanner Steed, Sasha Lupichuk
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100401- (2021)
Introduction: Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative, node negative (NN) breast cancer may be offered a gene expression profiling (GEP) test to determine recurrence risk and benefit of a
Externí odkaz:
https://doaj.org/article/efbfe1e45e4b432180f6da3ef86b1bf9
Autor:
Magdalene Hope Maung, Judith Hugh
Publikováno v:
Human Pathology: Case Reports, Vol 9, Iss , Pp 5-9 (2017)
In 2013, approximately 660,000 Americans had end stage renal disease (ESRD), requiring either dialysis or transplantation. Up to 5% of dialysis dependent patients may develop calcific uremic arteriolopathy or calciphylaxis (CPX) with vascular medial
Externí odkaz:
https://doaj.org/article/d2d11a0981aa4fb1a0fc61fbf9f573cd
Publikováno v:
IEEE Transactions on Medical Imaging. 38:2632-2641
Automated cell detection and localization from microscopy images are significant tasks in biomedical research and clinical practice. In this paper, we design a new cell detection and localization algorithm that combines deep convolutional neural netw
Autor:
Giuseppe Viale, Zuzana Kos, Allen M Gown, John M. S. Bartlett, Samuel C Y Leung, Andrew Dodson, Dongxia Gao, Frédérique Penault-Llorca, Jane Starczynski, Roberto Salgado, Mauro G. Mastropasqua, Sharon Nofech-Mozes, C. Kent Osborne, Signe Borgquist, Mitch Dowsett, Bert van der Vegt, Torsten O. Nielsen, Takuya Moriya, Takashi Sakatani, Tammy Piper, Carolina Gutierrez, Tomoharu Sugie, Anita Bane, Martin C. Chang, Susan Fineberg, Cornelia M Focke, Lila Zabaglo, Anna Ehinger, Lisa M. McShane, Sunil Badve, Daniel F. Hayes, Judith Hugh, Anne-Vibeke Lænkholm, Indu Arun
Publikováno v:
Histopathology, 75(2), 225-235. Wiley
Leung, S C Y, Nielsen, T O, Zabaglo, L A, Arun, I, Badve, S S, Bane, A L, Bartlett, J M S, Borgquist, S, Chang, M C, Dodson, A, Ehinger, A, Fineberg, S, Focke, C M, Gao, D, Gown, A M, Gutierrez, C, Hugh, J C, Kos, Z, Lænkholm, A, Mastropasqua, M G, Moriya, T, Nofech-mozes, S, Osborne, C K, Penault-llorca, F M, Piper, T, Sakatani, T, Salgado, R, Starczynski, J, Sugie, T, Vegt, B, Viale, G, Hayes, D F, Mcshane, L M & Dowsett, M 2019, ' Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration ', Histopathology . https://doi.org/10.1111/his.13880
Leung, S C Y, Nielsen, T O, Zabaglo, L A, Arun, I, Badve, S S, Bane, A L, Bartlett, J M S, Borgquist, S, Chang, M C, Dodson, A, Ehinger, A, Fineberg, S, Focke, C M, Gao, D, Gown, A M, Gutierrez, C, Hugh, J C, Kos, Z, Lænkholm, A V, Mastropasqua, M G, Moriya, T, Nofech-Mozes, S, Osborne, C K, Penault-Llorca, F M, Piper, T, Sakatani, T, Salgado, R, Starczynski, J, Sugie, T, van der Vegt, B, Viale, G, Hayes, D F, McShane, L M, Dowsett, M & on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) 2019, ' Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections : an international multicentre collaboration ', Histopathology, vol. 75, no. 2, pp. 225-235 . https://doi.org/10.1111/his.13880
Leung, S C Y, Nielsen, T O, Zabaglo, L A, Arun, I, Badve, S S, Bane, A L, Bartlett, J M S, Borgquist, S, Chang, M C, Dodson, A, Ehinger, A, Fineberg, S, Focke, C M, Gao, D, Gown, A M, Gutierrez, C, Hugh, J C, Kos, Z, Lænkholm, A, Mastropasqua, M G, Moriya, T, Nofech-mozes, S, Osborne, C K, Penault-llorca, F M, Piper, T, Sakatani, T, Salgado, R, Starczynski, J, Sugie, T, Vegt, B, Viale, G, Hayes, D F, Mcshane, L M & Dowsett, M 2019, ' Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration ', Histopathology . https://doi.org/10.1111/his.13880
Leung, S C Y, Nielsen, T O, Zabaglo, L A, Arun, I, Badve, S S, Bane, A L, Bartlett, J M S, Borgquist, S, Chang, M C, Dodson, A, Ehinger, A, Fineberg, S, Focke, C M, Gao, D, Gown, A M, Gutierrez, C, Hugh, J C, Kos, Z, Lænkholm, A V, Mastropasqua, M G, Moriya, T, Nofech-Mozes, S, Osborne, C K, Penault-Llorca, F M, Piper, T, Sakatani, T, Salgado, R, Starczynski, J, Sugie, T, van der Vegt, B, Viale, G, Hayes, D F, McShane, L M, Dowsett, M & on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) 2019, ' Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections : an international multicentre collaboration ', Histopathology, vol. 75, no. 2, pp. 225-235 . https://doi.org/10.1111/his.13880
Aims: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The International Ki67 in Breast Can
Autor:
Tammy Piper, Joema Lima, Anita Bane, Daniel F. Hayes, Chad Galderisi, Mitch Dowsett, Lisa M. McShane, Keith W. Miller, Jason Ruan, Samuel C Y Leung, Martin C. Chang, David L. Rimm, Torsten O. Nielsen, Malini Srinivasan, Yalai Bai, Shakeel Virk, John M. S. Bartlett, Hua Yang, Carsten Denkert, Michelle Dean, Judith Hugh, Richard M. Levenson, Emeka K. Enwere, Arvydas Laurinavicius, Ying Wu, Elizabeth N. Kornaga, Abhi Gholap, Anagha P. Jadhav, Liron Pantanowitz, Jane Bayani
Publikováno v:
Modern Pathology. 32:59-69
The nuclear proliferation biomarker Ki67 has potential prognostic, predictive, and monitoring roles in breast cancer. Unacceptable between-laboratory variability has limited its clinical value. The International Ki67 in Breast Cancer Working Group in
Autor:
Tasnima Abedin, Tanner Steed, Gilbert Bigras, Atul Batra, Judith Hugh, Karen King, Gloria Roldan-Urgoiti, NA Nixon, Sasha Lupichuk, Malek B. Hannouf
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100401-(2021)
Introduction: Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative, node negative (NN) breast cancer may be offered a gene expression profiling (GEP) test to determine recurrence risk and benefit of a
Autor:
Daniel Nisakar Meenakshi Sundaram, Hasan Uludağ, Robert A. Maranchuk, Raimar Löbenberg, Hamidreza Montazeri Aliabadi, Judith Hugh, Manoj B. Parmar, K C Remant Bahadur
Publikováno v:
Acta Biomaterialia. 66:294-309
Triple-negative breast cancer is an aggressive form of breast cancer with few therapeutic options if it recurs after adjuvant chemotherapy. RNA interference could be an alternative therapy for metastatic breast cancer, where small interfering RNA (si
Autor:
Judith Hugh, Hua Yang, Richard Berendt, Gilbert Bigras, George Wood, Wei-Feng Dong, Sarah Canil
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
There is a pressing need for an objective decision tool to guide therapy for breast cancer patients that are estrogen receptor positive and HER2/neu negative. This subset of patients contains a mixture of luminal A and B tumors with good and bad outc
Autor:
Vrajesh Pandya, Todd McMullen, Judith Hugh, Richard A. Veldhoen, Sambasivarao Damaraju, John R. Mackey, Ing Swie Goping, Namrata Patel, John Maringa Githaka
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 6, Pp 1-19 (2020)
Cell Death and Disease, Vol 11, Iss 6, Pp 1-19 (2020)
Apoptosis is fundamental to normal animal development and is the target for many anticancer therapies. Recent studies have explored the consequences of “failed apoptosis” where the apoptotic program is initiated but does not go to completion and
Publikováno v:
Molecular Pharmaceutics. 13:4116-4128
Cancer cells are known to be heterogeneous and plastic, which imparts innate and acquired abilities to resist molecular targeting by short interfering RNA (siRNA). Not all cancer cells in a population would show a similar responsiveness to targeting